Explore LENN nanoparticles, a groundbreaking technology for delivering mRNA therapies to bladder cancer cells with enhanced ...
Research about LENN -- a patent-pending, virus-mimicking platform technology that targets bladder cancer cells with mRNA ...
News Medical on MSN
Purdue-developed LENN system enhances stability and targeting of mRNA cancer therapies
Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...
AZoLifeSciences on MSN
Life science and biotech trends for 2026
Advancements in AI, multi-omics, and genome editing are transforming life sciences and biotechnology, addressing new ...
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...
Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...
Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well ...
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...
Historically, knowledge of the function and therapeutic potential of a protein preceded identification and cloning of its corresponding gene. Today, high-throughput screening and sequencing have ...
The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback